Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) — Financial Flexibility Index
Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) has a Financial Flexibility Index of -0.82x as of September 2025. Free cash flow of $-4.45 Million (operating CF $-4.51 Million minus capex $60.38K) represents -1% of total liabilities ($5.43 Million). Check Eupraxia Pharmaceuticals Inc. Common Sto investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Eupraxia Pharmaceuticals Inc. Common Stock Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for Eupraxia Pharmaceuticals Inc. Common Stock across 8 annual periods. For the full cash flow conversion analysis, see EPRX cash flow metrics.
Annual Financial Flexibility Index for Eupraxia Pharmaceuticals Inc. Common Stock (2017–2024)
Year-by-year free cash flow to debt coverage for Eupraxia Pharmaceuticals Inc. Common Stock. Explore how well can Eupraxia Pharmaceuticals Inc. Common Sto service its debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -9.63x | $-29.89 Million | $-29.99 Million | $3.10 Million | ▼ -802.5% |
| 2023 | -1.07x | $-20.68 Million | $-20.75 Million | $19.37 Million | ▼ -21.6% |
| 2022 | -0.88x | $-14.16 Million | $-14.40 Million | $16.13 Million | ▲ +5.4% |
| 2021 | -0.93x | $-11.23 Million | $-11.58 Million | $12.10 Million | ▼ -5213.8% |
| 2020 | -0.02x | $-403.78K | $-403.78K | $23.12 Million | ▲ +92.8% |
| 2019 | -0.24x | $-5.16 Million | $-5.17 Million | $21.42 Million | ▲ +57.7% |
| 2018 | -0.57x | $-8.18 Million | $-8.32 Million | $14.34 Million | ▲ +91.6% |
| 2017 | -6.77x | $-4.98 Million | $-5.30 Million | $735.82K | — |